Do you want to read an article? Please log in or register.
Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis
Lipid-Lowering Drugs
RECOMMENDED
Related content
Heart, Artery and Coronary DiseasesLipid-Lowering Drugs
Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia
JAMA Cardiol.
Banach M, Duell PB, Gotto AM Jr, Laufs U, Leiter LA, Mancini GBJ, Ray KK, Flaim J, Ye Z, Catapano AL
doi: 10.1001/jamacardio.2020.2314.
Heart, Artery and Coronary DiseasesLipid-Lowering Drugs
Does Evolocumab, as a PCSK9 Inhibitor, Ameliorate the Lipid Profile in Familial Hypercholesterolemia Patients? A Meta-Analysis of Randomized Controlled Trials
J Pharm Pharm Sci.
Eslami SM, Nikfar S, Ghasemi M, Abdollahi M
doi: 10.18433/J36C8N.
Cardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesLipid-Lowering DrugsTherapy and Intervention
Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials
Atherosclerosis.
Kereiakes DJ, Lepor NE, Gerber R, Veronica Lee L, Elassal J, Thompson D, Michael Gibson C
doi: 10.1016/j.atherosclerosis.
RECOMMENDED
Lipid-Lowering Drugs
Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control
Atherosclerosis.
Vallejo-Vaz AJ, Ray KK, Ginsberg HN, Davidson MH, Eckel RH, Lee LV, Bessac L, Pordy R, Letierce A, Cannon CP
doi: 10.1016/
Therapy and Intervention
The Smoker's Paradox Revisited: A Patient-Level Pooled Analysis of 18 Randomized Controlled Trials
JACC Cardiovasc Interv.
Yadav M, Mintz GS, Généreux P, Liu M, McAndrew T, Redfors B, Madhavan MV, Leon MB, Stone GW
doi: 10.1016/j.jcin.2019.06.034.
Atrial Fibrillation
Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials
Eur Heart J.
Henry TD, Losordo DW, Traverse JH, Schatz RA, Jolicoeur EM, Schaer GL, Clare R, Chiswell K, White CJ, Fortuin FD, Kereiakes DJ, Zeiher AM, Sherman W, Hunt AS, Povsic TJ
doi: 10.1093/eurheartj/ehx764.
Therapy and Intervention
New-generation drug-eluting coronary stents in octogenarians: Patient-level pooled analysis from the TWENTE I-IV trials
Am Heart J.
Ploumen EH, Buiten RA, Doggen CJM, Stoel MG, van Houwelingen KG, Schotborgh CE, Jessurun GAJ, Roguin A, Danse PW, Benit E, Aminian A, Linssen GCM, de Man FHAF, Hartmann M, Buiten DG, Kok MM, Zocca P, von Birgelen C, TWENTE I-IV trial investigators.
doi: 10.1016/j.ahj.
RECOMMENDED
Lipid-Lowering Drugs
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
N Engl J Med.
Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, Wijngaard PLJ, Curcio D, Jaros MJ, Leiter LA, Kastelein JJP, ORION-9 Investigators.
doi: 10.1056/NEJMoa1913805.
Cardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesLipid-Lowering Drugs
Alirocumab Treatment and Achievement of Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials
J Am Heart Assoc.
Bays HE, Leiter LA, Colhoun HM, Thompson D, Bessac L, Pordy R, Toth PP
doi: 10.1161/JAHA.117.005639.